SILUMBRA suvorexant 20mg tablet blister pack

Valsts: Austrālija

Valoda: angļu

Klimata pārmaiņas: Department of Health (Therapeutic Goods Administration)

Aktīvā sastāvdaļa:

suvorexant, Quantity: 20 mg

Pieejams no:

Merck Sharp & Dohme (Australia) Pty Ltd

SNN (starptautisko nepatentēto nosaukumu):

suvorexant

Zāļu forma:

Tablet, film coated

Kompozīcija:

Excipient Ingredients: lactose monohydrate; magnesium stearate; microcrystalline cellulose; copovidone; croscarmellose sodium; titanium dioxide; hypromellose; triacetin

Ievadīšanas:

Oral

Vienības iepakojumā:

30 tablets, 3 tablets, 10 tablets

Receptes veids:

(S4) Prescription Only Medicine

Ārstēšanas norādes:

SILUMBRA is indicated for the treatment of insomnia, characterised by difficulties with sleep onset and/or sleep maintenance. Following initiation of treatment, continuation should be re-evaluated after 3 months [see Pharmacodynamic Properties, Clinical trials and Adverse Effects (Undesirable Effects) for clinical trial durations].

Produktu pārskats:

Visual Identification: White, round, biconvex, film coated tablet, marked with MSD logo and 335 on one side, and plain on the other side.; Container Type: Blister Pack; Container Material: Al/Al; Container Life Time: 36 Months; Container Temperature: Store below 25 degrees Celsius; Container Closure: Child resistant closure

Autorizācija statuss:

Registered

Autorizācija datums:

2016-11-16